The GWC network invested £800k in Sphere Fluidics’ latest funding round which was over subscribed. Sphere Fluidics is a Cambridge University spin out with world leading technology which makes it possible to screen tens of millions of cells. It provides you with the best chance of finding that rare and valuable variant, whether it’s a diseased cell, a valuable biological product or a rare genetic variant. As it can process millions of cells a day, their technology is also perfect for high throughput screening and processing applications.
Their proprietary microfluidic technology that allows the ultra-high throughput analysis of isolated cells in miniaturised (pL to nL) picodroplets. This technology is adopted by their systems to enable faster, less costly and more effective sample screening and biological discovery.